273 related articles for article (PubMed ID: 6972529)
1. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S
Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529
[TBL] [Abstract][Full Text] [Related]
2. Use of 1,25(OH)2-vitamin D3 in prevention of renal osteodystrophy: preliminary observations.
Baker LR; Muir JW; Cattell WR; Tucker KA; Sharman VL; Goodwin FJ; Marsh FP; Hately W; Morgan AG; de Saintonge DM
Contrib Nephrol; 1980; 18():147-51. PubMed ID: 7353373
[TBL] [Abstract][Full Text] [Related]
3. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
Massry SG; Goldstein DA; Malluche HH
Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
[No Abstract] [Full Text] [Related]
4. Calcitriol in dialysis patients.
Maxwell DR; Benjamin DM; Donahay SL; Allen MK; Hamburger RJ; Luft FC
Clin Pharmacol Ther; 1978 May; 23(5):515-9. PubMed ID: 205382
[TBL] [Abstract][Full Text] [Related]
5. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
[TBL] [Abstract][Full Text] [Related]
6. Assessment of combined 24,25(OH)2D3 and 1 alpha (OH)D3 therapy for bone disease in dialysis patients.
Popovtzer MM; Levi J; Bar-Khayim Y; Shasha SM; Boner G; Bernheim J; Chaimovitz C; Rubinger D; Gafter U; Gazit D
Bone; 1992; 13(5):369-77. PubMed ID: 1419378
[TBL] [Abstract][Full Text] [Related]
7. 1,25-dihydroxycholecalciferol in renal osteodystrophy. Epiphysiolysis--anticonvulsant therapy.
Pierides AM; Ellis HA; Dellagrammatikas H; Scott JE; Norman AW
Arch Dis Child; 1977 Jun; 52(6):464-72. PubMed ID: 879832
[TBL] [Abstract][Full Text] [Related]
8. 1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration alone.
Coen G; Taccone Gallucci M; Bonucci E; Ballanti P; Bianchi AR; Bianchini G; Matteucci MC; Mazzaferro S; Picca S; Taggi F; Cinotti GA; Casciani CU
Miner Electrolyte Metab; 1983; 9(1):19-27. PubMed ID: 6687749
[No Abstract] [Full Text] [Related]
9. Long-term therapy of uremic osteodystrophy in adults with calcitriol.
Moorthy AV; Harrington AR; Mazess RB; Simpson DP
Clin Nephrol; 1981 Aug; 16(2):93-100. PubMed ID: 6894893
[TBL] [Abstract][Full Text] [Related]
10. Influence of long-term oral 1,25-dihydroxyvitamin D in childhood renal osteodystrophy.
Chesney RW; Hamstra A; Jax DK; Mazess RB; DeLuca HF
Contrib Nephrol; 1980; 18():55-71. PubMed ID: 7353380
[No Abstract] [Full Text] [Related]
11. Decreased renal function in association with administration of 1,25-dihydroxyvitamin D3 to patients with stable, advanced renal failure.
Christiansen C; Røodbro P; Christensen MS; Naestoft J; Hartnack B; Transbøol I
Contrib Nephrol; 1980; 18():139-46. PubMed ID: 6243527
[TBL] [Abstract][Full Text] [Related]
12. Current status of the use of newer analogs of vitamin D in the management of renal osteodystrophy.
Coburn JW; Brickman AS
Adv Exp Med Biol; 1978; 103():473-86. PubMed ID: 362852
[No Abstract] [Full Text] [Related]
13. Vitamin D metabolites and bone mineralization in man.
Bordier P; Rasmussen H; Marie P; Miravet L; Gueris J; Ryckwaert A
J Clin Endocrinol Metab; 1978 Feb; 46(2):284-94. PubMed ID: 750606
[TBL] [Abstract][Full Text] [Related]
14. Renal hypophosphatemic rickets: growth acceleration after long-term treatment with 1,25-dihydroxyvitamin-D3.
Chan JC; Lovinger RD; Mamunes P
Pediatrics; 1980 Sep; 66(3):445-54. PubMed ID: 6893489
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.
Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Eade Y; Johnson JR; George CR; Collett P
Miner Electrolyte Metab; 1985; 11(6):358-68. PubMed ID: 3877862
[TBL] [Abstract][Full Text] [Related]
16. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.
Berl T; Berns AS; Hufer WE; Hammill K; Alfrey AC; Arnaud CD; Schrier RW
Ann Intern Med; 1978 Jun; 88(6):774-80. PubMed ID: 208439
[TBL] [Abstract][Full Text] [Related]
17. Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium.
Winney RJ; Bone JM; Anderson TJ; Robson JS
Calcif Tissue Res; 1977 May; 22 Suppl():94-100. PubMed ID: 912593
[No Abstract] [Full Text] [Related]
18. 1,25-Dihydroxycholecalciferol in dialysed patients with clinically asymptomatic renal osteodystrophy. A controlled study.
Fischer JA; Binswanger U
Contrib Nephrol; 1980; 18():82-91. PubMed ID: 7353381
[TBL] [Abstract][Full Text] [Related]
19. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3.
Voigts AL; Felsenfeld AJ; Llach F
Arch Intern Med; 1983 Jun; 143(6):1205-11. PubMed ID: 6344827
[TBL] [Abstract][Full Text] [Related]
20. Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy.
Coburn JW; Brickman AS; Sherrard DJ; Singer FR; Wong EG; Baylink DJ; Norman AW
Proc Eur Dial Transplant Assoc; 1977; 14():442-50. PubMed ID: 600961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
